PERIOGARD MOUTHWASH
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
03-12-2019
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
CHLORHEXIDINE GLUCONATE
Fáanlegur frá:
COLGATE-PALMOLIVE CANADA INC
ATC númer:
A01AB03
INN (Alþjóðlegt nafn):
CHLORHEXIDINE
Skammtar:
0.12%
Lyfjaform:
MOUTHWASH
Samsetning:
CHLORHEXIDINE GLUCONATE 0.12%
Stjórnsýsluleið:
BUCCAL
Einingar í pakka:
470ML
Gerð lyfseðils:
Prescription
Lækningarsvæði:
MISCELLANEOUS ANTI-INFECTIVES
Vörulýsing:
Active ingredient group (AIG) number: 0107629007; AHFS:
Leyfisstaða:
CANCELLED POST MARKET
Leyfisdagur:
2018-10-10
Vara einkenni
Page 1 of 19
PRODUCT MONOGRAPH
PERIOGARD
Chlorhexidine Gluconate 0.12% Oral Rinse, USP
Liquid, 0.12% Chlorhexidine Gluconate
Antigingivital Oral Rinse
Colgate-Palmolive Canada Inc. Date of Revision:
Two Morneau Shepell Centre
December 3, 2019
5
th
Floor, 895 Don Mills Road
Toronto, Ontario M3C 1W3
Submission Control No: 232067
Page 2 of 19
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
3
SUMMARY PRODUCT INFORMATION
.............................................................................................
3
INDICATIONS AND CLINICAL USE
...................................................................................................
3
CONTRAINDICATIONS
.......................................................................................................................
4
WARNINGS AND PRECAUTIONS
.....................................................................................................
4
ADVERSE REACTIONS
.......................................................................................................................
5
DOSAGE AND ADMINISTRATION
.....................................................................................................
6
OVERDOSAGE
.....................................................................................................................................
7
ACTION AND CLINICAL PHARMACOLOGY
.....................................................................................
8
STORAGE AND STABILITY
................................................................................................................
9
SPECIAL HANDLING INSTRUCTIONS
............................................................................................
10
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................................. 10
PART II: SCIENTIFIC INFORMATION
..................................................................................................
11
P
Lestu allt skjalið
